MiR-145, a new regulator of the DNA Fragmentation Factor-45 (DFF45)-mediated apoptotic network
© Zhang et al; licensee BioMed Central Ltd. 2010
Received: 25 February 2010
Accepted: 6 August 2010
Published: 6 August 2010
MicroRNA-145 (miR-145) is considered to play key roles in many cellular processes, such as proliferation, differentiation and apoptosis, by inhibiting target gene expression. DNA Fragmentation Factor-45 (DFF45) has been found to be the substrate of Caspase-3, and the cleavage of DFF45 by caspase-3 during apoptosis releases DFF40 that degrades chromosomal DNA into nucleosomal fragments. There are currently no in-depth studies on the relationship between miR-145 and the DFF45 gene.
In this study, we identified DFF45 as a novel target of miR-145. We demonstrated that miR-145 targets a putative binding site in the coding sequence (CDS) of DFF45, and its abundance is inversely associated with DFF45 expression in colon cancer cells. Using a luciferase reporter system, we found that miR-145 suppresses the expression of the luciferase reporter gene fused to the putative binding site of DFF45. The level of DFF45 protein, but not DFF45 mRNA, was decreased by miR-145, suggesting a mechanism of translational regulation. Furthermore, we demonstrate that this specific silencing of DFF45 by miR-145 accounts, at least in part, for the staurosporine-induced tumor cell apoptosis in vitro.
Our study reveals a previously unrecognized function of miR-145 in DFF45 processing, which may underlie crucial aspects of cancer biology.
MicroRNAs are important post-transcriptional regulators of gene expression that control diverse physiological and pathological processes, this control allows for fine-tuning of the cellular processes, including regulation of proliferation, differentiation and apoptosis . MicroRNAs are initially transcribed as long primary miRNA by RNA polymerase II or III, and cleaved sequentially by the microprocessor complex Drosha-DGCR8 to yield the precursor miRNA in the nucleus. Precursor miRNA is then exported from the nucleus and processed in the cytoplasm by Dicer. The mature miRNA is loaded together with Ago2 proteins into the RNA-induced silencing complex (RISC), where it guides RISC to silence target mRNAs through mRNA cleavage, translational repression, or deadenylation [2–4]. Most notably, changes in the abundance of a single miRNA may affect the levels of expression of hundreds of different proteins [5, 6]. Although the number of verified human miRNAs is still expanding, the functions of only a few of them have been described. Recent studies have shown that the deregulation of microRNA expression contributes to the multistep processes of carcinogenesis in human cancer, either by oncogenetic or tumor suppressor function [7, 8].
A putative tumor suppressing miRNA, miR-145, has been shown to be decreased in various human cancers [9–13], and it decreases the apoptosis and proliferation rate of colorectal cancer cells . We have demonstrated that miR-145 targets a putative binding site in the 3'-UTR of the Friend leukemia virus integration 1 (Fli-1) gene, and its abundance is inversely related with Fli-1 expression in colon cancer tissues (data not shown). Some other targets of miR-145 include important regulators of cell apoptosis and proliferation, such as c-Myc and IRS-1 [15, 16]. IRS-1, a docking protein for both the type 1 insulin-like growth factor receptor and the insulin receptor, delivers anti-apoptotic and anti-differentiation signals. MiR-145 also down-regulates the proto-oncogene c-Myc, whose aberrant expression is associated with aggressive and poorly differentiated tumors. Recently, the roles of miRNAs in cellular apoptosis have been explored widely. However, the connection between apoptotic networks and miRNA biogenesis machineries has not been investigated in depth [17–20].
In this report, we demonstrate that DFF45 expression is controlled at the translational level by miR-145, using bioinformatic and proteomic techniques. DFF45 is a caspase-3 or caspase-7 substrate that must be cleaved before apoptotic DNA fragmentation can proceed [21, 22]. DFF45 exists as a heterodimer with a 40 kDa endonuclease termed DFF40, by a conserved domain of 80 amino acids at their N-terminus [23, 24]. DFF45 serves as both a specific inhibitor of DFF40 and as a molecular chaperone to allow for the appropriate folding of DFF40 to become an activatable nuclease [25–27]. During apoptosis, Caspase-3 and Caspase-7-mediated cleavage of DFF45 induces the release and activation of DFF40, leading to the generation of double-stranded breaks in inter-nucleosomal chromatin regions and chromatin condensation . The presence of this DNA ladder has been used extensively as a typical biochemical marker for apoptotic cell death [22, 26, 29]. Thus, the DFF45 may play a role in malignant transformation and metastasis, and up- or down-regulation of DFF45 expression might correlate with aggressive cancers [30, 31]. By gain-of-function and loss-of function approaches, we showed that the endogenous levels of DFF45 are controlled post-transcriptionally by miR-145 in human colon cancer cells. We further investigated the function of miR-145 in apoptosis, and showed that miR-145 is necessary and sufficient to modulate the apoptotic progression through the DFF45 pathway.
Mature miR-145 is down-regulated in colon cancer cells
Expression of DFF45 is inversely related to that of miR-145 in colon cancer cells
LS174T cells that express very little mature miR-145 were tranfected with a miR-145 mimic and its inhibitor. The ectopic expression of mature miR-145 was confirmed by the Hairpin-it™miRNAs Real-Time PCR Quantitation Assay. As expected, about a 6-fold increase in mature miR-145 was detected in the miR-145 mimic-transfected cells. In contrast, transfection with the miR-145 inhibitor reduced mature miR-145 by almost 50% in LS174T cells (Fig. 1B).
The five most significantly decreased proteins in the miR-145 mimic-treated group relative to the control.
Standard value (M*)
Standard value (C*)
MiR-145 targets a putative binding site in the coding sequence of DFF45
We chemically synthesized these putative binding sites, and tested their functions by cloning them into the Xba1 site of the pGL3 reporter vector (Fig. 2B). Using this reporter system, a functional putative binding site was identified by simply measuring luciferase activity. In LS174T cells, only the upstream binding site (854~876) responded to miR-145 over-expressed exogenously (Fig. 2C), and in normal colon cells endogenously over-expressing miR-145 (Fig. 2D).
Specific targeting of the DFF45 putative binding site by miR-145
To further demonstrate the importance of the putative binding site (854~876), a substitution mutation was generated to test its activity. In the DFF45-854-Mutation vector, seven nucleotides (gagcGgga) were replaced with ctcgGcct (Fig. 3C). We cloned the entire region (coding region plus 3'UTR) of DFF45 downstream of the reporter. As expected, down-regulation of reporter activity was detected in the construct that contains the entire region of DFF45. Correspondingly, we demonstrated that the mutation in the putative binding site (854~876) abolished the miR-145-mediated inhibition of the reporter gene (Fig. 3D). Taken together, these data suggest that the miR-145 binding site (854~876) present in the DFF45 is critical for miR-145-mediated gene regulation.
MiR-145 regulates DFF45 at the translational level
Detection of apoptosis by DNA fragmentation
Morphology of apoptosis detected by Hoechst staining
Given the great importance of DFF45 in apoptotic networks, it is reasonable to propose that a proper expression level of DFF45 will be required to achieve sensitivity to drug-induced apoptosis, and that up- or down-regulation of DFF45 expression might correlate with cancer aggression. Induction of DFF45 seems to be involved in the production of heterogenous subclones in human gastric cancer cells, and in their enhanced ability to avoid apoptosis . Hara et al. found that when DFF45 is overexpressed in human renal cell carcinoma cells, it renders them highly resistant to therapy-induced apoptosis [36, 37]. Additionally, thymocytes from DFF45 mutant mice exhibit neither DNA laddering nor chromatin condensation when exposed to apoptotic stimuli [38, 39]. DFF45 was expressed preferably in low-stage neuroblastoma tumors, and to a lesser degree in high-stage neuroblastomas . However, the molecular mechanism resulting in aberrant expression of human DFF45 in cancer cells is poorly understood.
In this report, we show that DFF45 is a direct target for miR-145. Our studies indicated that the levels of mature miR-145 were significantly lower in colon cancer cells compared with their levels in normal colon cells. Antibody microarray and Western blotting analyses on suitably prepared cell extracts showed that DFF45 levels in colon cancer cells far exceed the levels exhibited by normal colon cells (Fig. 1). There may have been a relationship between these differences in DFF45 levels and miR-145 levels. Based on these results, we selected LS174T cells for further studies. Using a luciferase reporter system, we identified a putative binding site in the CDS of human DFF45 for miR-145 (Figs. 2, 3). In LS174T cells, the miR-145 can negatively regulate DFF45 expression at the translational level (Fig. 4). The importance of miR-145 in this response was confirmed by transfection of the miR-145 mimic into LS174T cells, and the restoration of DNA fragmentation or chromatin condensation to levels similar to that of normal colon cells (Figs. 5, 6). Further, on the basis of the modest protein silencing observed in these studies, miR-145 may act to fine-tune protein expression rather than acting as an all-or-none switch. These results provided a mechanism for how the regulation of DFF45 signaling causes cancer cells to become sensitive to drug-induced apoptosis.
We also tested the expression of p53 protein that is lost or mutated in more than half of all human cancers . p53 is a transcription factor that induces the expression of miR-145 by interacting with a potential p53 response element in the miR-145 promoter . Additionally, in response to DNA damage, p53 interacts with the Drosha processing complex, and facilitates the processing of primary miR-145 to precursor miR-145 . It is possible that the loss of p53 function may fail to stimulate miR-145 expression. Consistently, precursor miR-145 or mature miR-145 was decreased in all colon tumor cells tested, all of which had down-regulated wild-type or mutant p53 protein (Fig. 1). Based on these results, an appealing hypothesis to explain the miR-145 suppression observed in colon cancer cells is that it is linked to a deficit in miRNA processing, and there is no relation between processing of primary miR-145 to precursor miR-145 and the p53 status (wild-type or mutant).
Together, our results define the role of miR-145 in the posttranscriptional regulation of DFF45, and suggest that miR-145 provides a possible link between p53 and DFF45 in this gene regulatory network. The potential use of a natural miRNA to sensitize cells to execute full-blown apoptosis is exciting, and will hopefully lead to a new therapeutic strategy for the treatment of colon cancer.
Our study revealed a previously unrecognized function of miR-145 in DFF45 processing; this function may underlie crucial aspects of cancer biology. This function may provide the possibility that the effect of chemotherapeutics for human colon cancer may be improved by utilization of miR-145 in the near future.
Methods and materials
Tumor cells and materials
Human colon cancer cells SW480 (ATCC Number: CCL-228™), LS174T (ATCC Number: CL-188™), SW620 (ATCC Number: CCL-227™), COLO320DM (ATCC Number: CCL-220™) and COLO205 (ATCC Number: CCL-222™) were obtained from American Type Culture Collection. Normal colon cells were collected at Renji hospital, Shanghai, China. Fresh tissue samples were immediately put into liquid nitrogen, followed by primary culture in DMEM high glucose medium containing antibiotics. MiR-145 mimic/inhibitor was purchased from Ambion (Austin, TX). SYBR Premix Ex Taq™(perfect Real Time) was obtained from Takara Bio (Madison, WI). DFF45 antibody and p53 antibody were purchased from ProteinTech Group Inc (Chicago, IL). SiRNA for DFF45 and control siRNA were purchased from GenePharma (Shanghai, China). Staurosporine was purchased from Sigma (Milwaukee, WI).
Transfection of cells was performed with Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. Briefly, the cells were seeded in 6-well plates at 30% confluence the day before transfection. MiR-145 mimic/inhibitor and miRNA control (50 nM each), were used for each transfection.
Antibody Microarray analysis
Forty-eight hours after transfection with miR-145 mimic, total protein was isolated from LS174T cells and measured using BCA Protein Assay Reagent (Pierce). A human Antibody Microarray-720 slides kit was purchased from SPRING BIOSCIENCE. Briefly, the membranes were blocked with a blocking buffer, and then 0.1 mg Biotin Labeled Protein Sample was added and incubated at room temperature for 2 h. The membranes were washed, and 1 ml of Streptavidin Solution was added and incubated at room temperature for 45 min. The membranes were incubated with 1 ml of Detection Antibody-Cy3 at room temperature for 45 min. The slides were exposed to film and processed by autoradiography.
MicroRNA and mRNA detection
QRT-PCR assays were performed for measurement of the expression levels of primary, precursor and mature miRNAs. Briefly, total RNA was extracted with a mirVana miRNA Isolation Kit (Ambion) and subjected to reverse transcription with the Reverse Transcription kit (Promega). QRT-PCR was performed with the Rotogene 3000 real time PCR system. For detection of mature miRNAs, Hairpin-it™miRNAs Real-Time PCR Quantitation Kit (GenePharma, China) was used in accordance with the manufacturer's protocol. Results were normalized to U6 snRNA. For measurement of the primary and precursor miRNA expression, real-time PCR was performed using the SYBR method and β-actin RNA was used for normalization. The primer sequences used were pre-miR-145 forward 5'-GTCCA GTTTT CCCAG GAATC-3', reverse 5'-AGAAC AGTAT TTCCA GGAAT-3'; pri-miR-145 forward 5'-TGGAT TTGCC TCCTT CCCA-3', reverse 5'-TTGAA CCCTC ATCCT GTGAG CC-3'; β-actin forward 5'-TCACC CACAC TGTGC CCATC TACGA-3', reverse 5'-CAGCG GAACC GCTCA TTGCC AATGG-3'; U6 snRNA forward 5'-CTCGC TTCGG CAGCA CA-3', reverse 5'-AACGC TTCAC GAATT TGCGT-3' .
To detect relative levels of DFF45 mRNA, real-time PCR was performed using the SYBR method at the following conditions: 95°C 30 s, 1 cycle; 95°C 5 s, 55°C 20 s, 72°C 15 s, 40 cycles. PCR primers were DFF45 forward 5'-GTTGC CTTGA ACTGG GACA-3', reverse 5'-CGCTG CTGCT ATGTG GG-3'.
Bioinformatic prediction of miR-145 targets
Putative miR-145 binding sites in DFF45 genomic sequence were predicted by the RNA22 program based on minimizing folding energy and maximizing number of paired-up bases in heteroduplex http://cbcsrv.watson.ibm.com/rna22.html.
Though bioinformatic analysis, the putative binding site of miR-145 was chemically synthesized and cloned into pGL3 control vector (Promega) at Xba1 site. To construct the DFF45-854-Wild vector, the entire region (coding region plus 3'UTR) of DFF45 was amplified from the cDNA of LS174T cells using DFF45 PCR primers: forward-primer 5'-GGTCC CACCT TGTGG AGGAT and reverse-primer 5'-TGAGA CGGAG TCTCG CTCTG TT, and then cloned into the pGL3 control vector at Xba1 site. To create the DFF45-854-Mutation vector, seven nucleotides (TTCAG GAGGC CTGT gagcG ggaG) were changed for the reporter construct.
LS174T cells or normal colon cells were plated in triplicate wells of a 24-well plates and transfected with luciferase reporters fused with putative binding site for miR-145, and miR-145 mimic/inhibitor. Transfection efficiency was corrected by a renilla luciferase vector (pRL-CMV, Promega). The cells were harvested for luciferase assays 24 hour after transfection. The Dual-Luciferase Reporter Assay System (Promega) was used to measure the reporter activity according the manufacturer's protocol.
Western blotting assay
Protein concentration was measured using Pierce BCA Protein Assay Reagent (Thermo-Fisher Scientific, Rockford, IL). Cell lysates (50 μg) were electrophoresed through 10% polyacrylamide gels and transferred to a NC membrane. The membrance was incubated with DFF45 antibody or p53 antibody. Secondary antibodies were labeled with IRDyes. Signals were visualized using an Odyssey Infrared Imaging System.
Nuclear DNA fragmentation assay
LS174T cells (106) and normal colon cells were treated with the indicated chemicals for appropriate time point. Cells were incubated in lysis buffer [10 mmol/l Tris, 1 mmol/l EDTA, 100 mmol/l NaCl, 5 g/l SDS, 1 μg/μl RNase A, pH 8.0] at 37°C for 30 min. At the end of incubation, proteinase K was added to a final concentration of 0.1 mg/ml and the incubation was continued at 50°C for 8 h. DNA was extracted with phenol/chloroform and precipitated with ethanol. DNA pellets were dissolved in TE buffer and analyzed on a 1.5% agarose gel with UV light after ethidium bromide staining.
Cells were seeded on sterile cover glasses placed in the 12-well plates. When they grew to approximately 70% confluence, cells were washed twice in ice-cold PBS (pH 7.4). After washing, the cells were fixed with 4% paraformaldehyde in PBS for 30 minutes at 4°C, washed twice with PBS and stained with Hoechst 33258 (Invitrogen) at a final concentration of 10 μg/ml at room temperature for 5 min. Nuclear morphology was then examined using an IX71fluorescent microscope (Olympus).
All of the results are expressed as mean ± standard deviation. Statistical analysis was performed with Student's t-test for comparison of two groups. In both cases, differences with P < 0.05 were considered to be statistically significant.
This work was supported by the program of Shanghai Municipal Education Commission (jdy08054) to Haiyan Guo. The National Key Program for Basic Research of China (2010CB529902), The National Natural Science Foundation of China (30973663) to Guanxiang Qian. The Science and Technology Commission of Shanghai (08ZR1412500), The Innovation Program of Shanghai Municipal Education Commission (S30205, 09ZZ110) to Shengfang Ge. This work was supported by Science and Technology Commission of Shanghai (08DZ2271100) and supported by Shanghai Leading Academic Discipline Project (S30206).
- Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009, 11: 228-234. 10.1038/ncb0309-228View ArticlePubMed
- Eulalio A, Huntzinger E, Izaurralde E: Getting to the root of miRNA-mediated gene silencing. Cell. 2008, 132: 9-14. 10.1016/j.cell.2007.12.024View ArticlePubMed
- Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008, 9: 102-114. 10.1038/nrg2290View ArticlePubMed
- Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005, 6: 376-385. 10.1038/nrm1644View ArticlePubMed
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP: The impact of microRNAs on protein output. Nature. 2008, 455: 64-71. 10.1038/nature07242PubMed CentralView ArticlePubMed
- Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature. 2008, 455: 58-63. 10.1038/nature07228View ArticlePubMed
- Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269. 10.1038/nrc1840View ArticlePubMed
- Osada H, Takahashi T: MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007, 28: 2-12. 10.1093/carcin/bgl185View ArticlePubMed
- Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008, 27: 1788-1793. 10.1038/sj.onc.1210809View ArticlePubMed
- Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008, 68: 6416-6424. 10.1158/0008-5472.CAN-07-6110View ArticlePubMed
- Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN: Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67: 11612-11620. 10.1158/0008-5472.CAN-07-5019View ArticlePubMed
- Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008, 47: 1223-1232. 10.1002/hep.22158View ArticlePubMed
- Wang Y, Lee CG: MicroRNA and cancer--focus on apoptosis. J Cell Mol Med. 2009, 13: 12-23. 10.1111/j.1582-4934.2008.00510.xPubMed CentralView ArticlePubMed
- Akao Y, Nakagawa Y, Naoe T: MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 2007, 26: 311-320. 10.1089/dna.2006.0550View ArticlePubMed
- Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 2009, 106: 3207-3212. 10.1073/pnas.0808042106PubMed CentralView ArticlePubMed
- Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007, 282: 32582-32590. 10.1074/jbc.M702806200View ArticlePubMed
- Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E: Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem. 2009, 284: 26533-26546. 10.1074/jbc.M109.027466PubMed CentralView ArticlePubMed
- Lynam-Lennon N, Maher SG, Reynolds JV: The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009, 84: 55-71. 10.1111/j.1469-185X.2008.00061.xView ArticlePubMed
- Walker JC, Harland RM: microRNA-24a is required to repress apoptosis in the developing neural retina. Genes Dev. 2009, 23: 1046-1051. 10.1101/gad.1777709PubMed CentralView ArticlePubMed
- Xu J, Liao X, Wong C: Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer. 126: 1029-1035.
- Chiu CC, Lin CH, Fang K: Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis. 2005, 10: 643-650. 10.1007/s10495-005-1898-8View ArticlePubMed
- Liu X, Zou H, Slaughter C, Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 1997, 89: 175-184. 10.1016/S0092-8674(00)80197-XView ArticlePubMed
- Lugovskoy AA, Zhou P, Chou JJ, McCarty JS, Li P, Wagner G: Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis. Cell. 1999, 99: 747-755. 10.1016/S0092-8674(00)81672-4View ArticlePubMed
- Otomo T, Sakahira H, Uegaki K, Nagata S, Yamazaki T: Structure of the heterodimeric complex between CAD domains of CAD and ICAD. Nat Struct Biol. 2000, 7: 658-662. 10.1038/77957View ArticlePubMed
- Liu X, Li P, Widlak P, Zou H, Luo X, Garrard WT, Wang X: The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci USA. 1998, 95: 8461-8466. 10.1073/pnas.95.15.8461PubMed CentralView ArticlePubMed
- Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998, 391: 96-99. 10.1038/34214View ArticlePubMed
- Sakahira H, Enari M, Nagata S: Functional differences of two forms of the inhibitor of caspase-activated DNase, ICAD-L, and ICAD-S. J Biol Chem. 1999, 274: 15740-15744. 10.1074/jbc.274.22.15740View ArticlePubMed
- Widlak P, Li P, Wang X, Garrard WT: Cleavage preferences of the apoptotic endonuclease DFF40 (caspase-activated DNase or nuclease) on naked DNA and chromatin substrates. J Biol Chem. 2000, 275: 8226-8232. 10.1074/jbc.275.11.8226View ArticlePubMed
- Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998, 391: 43-50. 10.1038/34112View ArticlePubMed
- Charrier L, Jarry A, Toquet C, Bou-Hanna C, Chedorge M, Denis M, Vallette G, Laboisse CL: Growth phase-dependent expression of ICAD-L/DFF45 modulates the pattern of apoptosis in human colonic cancer cells. Cancer Res. 2002, 62: 2169-2174.PubMed
- Konishi S, Ishiguro H, Shibata Y, Kudo J, Terashita Y, Sugiura H, Koyama H, Kimura M, Sato A, Shinoda N: Decreased expression of DFF45/ICAD is correlated with a poor prognosis in patients with esophageal carcinoma. Cancer. 2002, 95: 2473-2478. 10.1002/cncr.10987View ArticlePubMed
- Mott JL: MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology. 2009, 50: 630-637. 10.1002/hep.23010PubMed CentralView ArticlePubMed
- Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL, Augenlicht LH: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003, 63: 8791-8812.PubMed
- Liu H, Qin CY, Han GQ, Xu HW, Meng M, Yang Z: Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J Gastroenterol. 2007, 13: 1652-1658.PubMed CentralView ArticlePubMed
- Sun A, Noriki S, Imamura Y, Fukuda M: Detection of cancer clones in human gastric adenoma by increased DNA-instability and other biomarkers. Eur J Histochem. 2003, 47: 111-122.View ArticlePubMed
- Hara S, Miyake H, Arakawa S, Kamidono S, Hara I: Over expression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo. J Urol. 2001, 166: 2491-2494. 10.1016/S0022-5347(05)65622-4View ArticlePubMed
- Rajandram R, Pat BK, Li J, Johnson DW, Gobe GC: Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology (Carlton). 2009, 14: 205-212. 10.1111/j.1440-1797.2008.01027.xView Article
- Zhang J, Liu X, Scherer DC, van Kaer L, Wang X, Xu M: Resistance to DNA fragmentation and chromatin condensation in mice lacking the DNA fragmentation factor 45. Proc Natl Acad Sci USA. 1998, 95: 12480-12485. 10.1073/pnas.95.21.12480PubMed CentralView ArticlePubMed
- Zhang J, Wang X, Bove KE, Xu M: DNA fragmentation factor 45-deficient cells are more resistant to apoptosis and exhibit different dying morphology than wild-type control cells. J Biol Chem. 1999, 274: 37450-37454. 10.1074/jbc.274.52.37450View ArticlePubMed
- Abel F, Sjoberg RM, Ejeskar K, Krona C, Martinsson T: Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. Br J Cancer. 2002, 86: 596-604. 10.1038/sj.bjc.6600111PubMed CentralView ArticlePubMed
- Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: Modulation of microRNA processing by p53. Nature. 2009, 460: 529-533. 10.1038/nature08199View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.